Essentials
• Impact of cancer stage on venous thromboembolism (VTE) risk is not well-known in all cancers.
• The Scandinavian Thrombosis and Cancer Cohort provides person-time data and validated VTEs.
• Impact of cancer stage on VTE incidence tended to vary with cancer type.
• Cancer stage may not per se be a risk factor for VTE in all cancer types.
Summary. Background: Absolute measures of the impact of cancer stage on the incidence of venous thromboembolism (VTE) in patients with distinct cancer types have not been investigated in a large population-based cohort study. Objectives: To investigate differences in the incidence rates of objectively confirmed VTE according to the development of cancer in a large population-based cohort study. Cancer type and stage at the time of diagnosis were taken into account. Patients and Methods: The Scandinavian Thrombosis and Cancer Cohort includes data regarding cancer types, stages and objectively confirmed VTE diagnoses among 144 952 participants followed from 1993 to 2012. We studied stage-specific incidence rates of VTE, and calculated incidence rate differences (IRDs) for VTE according to stages in patients with 10 types of solid cancer. Results: During the entire follow-up, 335 VTEs occurred, of which 293 occurred within 5 years. The IRD of VTE in patients with distant metastasis as compared with those with localized disease indicated large variation depending on cancer type. The highest IRD was observed for pancreatic cancer (IRD of 187.0 9 10 À3 person-years [p-y]; 95% confidence interval [CI] À 6.7 to 380.8), and the lowest IRD was observed for prostate cancer (IRD of 3.7 9 10 À3 p-y; 95% CI À 7 to 15.2). Regional spread as compared with localized disease also indicated large variation depending on cancer type; the highest IRD was observed for uterine cancer (IRD of 37.6 9 10 À3 p-y;
Introduction
Cohort studies have shown a substantially higher risk of venous thromboembolism (VTE) encompassing deep vein thrombosis and pulmonary embolism in cancer patients than in cancer-free controls [1, 2] . Cancer patients who develop VTE have poorer survival than patients without VTE, and an impaired quality of life [3] [4] [5] . The risk of VTE appears to vary by cancer site and stage, and the time since cancer diagnosis. Most VTEs occur within the first year after cancer diagnosis [6] [7] [8] .
Initial regional spread and distant metastasis of the cancer at diagnosis have been associated with a higher risk of VTE than localized disease in studies combining several cancer types [1, 9, 10] . Nevertheless, the pathophysiology differs between cancer types, so clustering of cancer types may mask different VTE risks for the different cancer types. Prior studies of single cancer types found that both regional spread and distant metastasis were associated with a higher risk of VTE than localized disease in most types of cancer, but few studies have assessed and compared the incidence rates (IRs) of VTE in patients with different types and stages of cancer [5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Different study objectives and, consequently, methods, time periods and study populations complicate comparison of the existing studies. The Scandinavian Thrombosis and Cancer (STAC) Cohort, with prospectively collected data, provides validated exposures and endpoints, and permits calculation of IRs [26] . Observations from the STAC Cohort are therefore valuable supplements to the knowledge available from existing studies on cancer-associated VTE.
The objective of this study was to investigate the incidence of VTE according to initial cancer stage in the STAC Cohort. We estimated stage-specific IRs, IR differences (IRDs), cumulative incidence proportions (CIPs) and hazard ratios (HRs) of VTE in patients with different types of solid cancer.
Methods

Study population
The STAC Cohort is a population-based cohort established to provide a comprehensive investigation of the impact of cancer development on the risk of VTE in the general population. The STAC Cohort was established by merging data from three large population-based cohort studies with enrollment in 1993-1997: from Norway, the Tromso Study and the Nord-Trondelag Health Study (HUNT); and from Denmark, the Diet, Cancer and Health (DCH) Study [27] [28] [29] . All participants were free of cancer and VTE at entry into the STAC Cohort, which includes, in total, 144 952 participants. We included the following 10 types of solid cancer in this study: lung, colorectal, upper gastrointestinal, pancreatic, breast, prostate, bladder, kidney, uterine and ovarian cancer. Patients with a VTE event prior to the diagnosis of cancer were excluded (n = 301), and five cases with two cancer diagnoses coded at the same date, 17 men diagnosed with breast cancer and eight cases without information on cancer stage were also excluded, leaving 10 583 cancer patients for this follow-up. Cases with stage that was actively coded 'unknown' were included. At enrollment, all participants gave their informed, written consent, permitting linkage by their civil personal registration (CPR) numbers (personal ID numbers; see below) to national healthcare registries. The cohort profile is described in detail elsewhere [26] .
Identification of cancer types and stages
In Denmark and Norway, a unique CPR number is assigned to every citizen at birth or at the time of immigration. The CPR number is provided by the respective Civil Registration Systems, which receive information on the vital status and emigration of citizens. This enables registry-based follow-up in epidemiologic studies. The CPR number is linked to all national registries. In Denmark and Norway, medical doctors are legally obliged to report cancer diagnoses and cancer stage at the time of diagnosis to the National Cancer Registries (NCRs). In cases of doubt about whether cancer stage should be coded as local, regional or distant metastasis, there was always an option for assigning 'unknown' as the cancer stage. Cancer-exposed participants of the STAC Cohort were identified by linking the CPR numbers to the respective NCRs, which are considered to be complete and valid [30] [31] [32] . Information on the date of cancer diagnosis and type and stage of cancer was obtained from the NCRs. Information on cancer type was given by ICD-10 codes from both NCRs.
According to the cancer staging system, solid cancers in Norway are categorized as 'localized, regional spread or distant metastasis' [33] . In Denmark, a similar classification system was used for solid cancers, excluding colorectal and gynecologic cancers, until 2004. For colorectal cancer, Duke's classification was used, and for gynecologic cancer the International Federation of Gynecology and Obstetrics (FIGO) classification was used, until 2004 [30] . Thereafter, cancer stage was coded according to the Tumor, Node, Metastasis (TNM) classification system in the Danish NCR for all solid cancer types [34] . We mapped TNM codes, Duke stages and FIGO stages into 'localized, regional spread and distant metastasis' terminology as recommended by the International Cancer Benchmark Partnership (ICBP) to align information on cancer stage in the STAC Cohort [35] . Cancers not covered by the ICBP work were mapped to the nomenclature 'localized', 'regional spread', and 'distant metastasis', guided by the TNM Classification of Malignant Tumors and the Surveillance, Epidemiology and End Results Summary Staging Manual [36, 37] (Table S1 ).
Identification and validation of VTE
First-time, symptomatic VTE was the outcome in this study. The identification and validation process has previously been published in detail [38] [39] [40] . In short, all identified cases of VTE were objectively confirmed by trained personnel by thorough review of medical records or discharge letters, biochemical investigations, and diagnostic images.
Statistics
Participants in the STAC Cohort registered with one of the 10 investigated cancer types during follow-up were included as exposed in this study. The outcome was firsttime VTE event. The date of study entry was the date of cancer diagnosis. The end of follow-up was 31 December 2012 for participants included in the Tromso Study, 31 December 2007 for participants included in the HUNT study, and 30 April 2008 for participants included in the DCH study; or date of death, emigration or VTE, whichever came first.
The occurrence of VTE was expressed as IRs, i.e. number of events per 1000 person years (p-y), with associated 95% confidence intervals (CIs). To illustrate the associations between cancer stage and the occurrence of VTE, we calculated IRDs. The IRDs between cancer stages and associated 95% CIs were estimated by use of the Poisson distribution. IRs and IRDs were calculated for two time periods: the first year after cancer diagnosis, and the first 5 years after cancer diagnosis. To determine absolute risks of VTE, we calculated the CIP. The CIP was calculated as the number of VTEs in subjects at risk from the date of cancer diagnosis until censoring, death was treated as competing risk. As the overall mortality in cancer patients is considerable, death was treated as a competing event [41] .
The HR of VTE was estimated with a Cox proportional-hazards regression model. In the regression analysis, we adjusted for age for all cancer sites and for sex for lung, colorectal, upper gastrointestinal, pancreatic, bladder and kidney cancer. Age was included as a continuous variable in the regression model, and linearity was evaluated by the use of restricted cubic spline variables. HRs for VTE 1 years and 5 years after cancer diagnosis were computed for cancer in total and for each cancer type. Localized cancer was used as a reference for assessment of impact on cancer stage in the HR for VTE in each cancer type.
We calculated IRs, IRDs, CIPs and HRs of VTE according to cancer stage for the 10 included cancer types combined and by cancer type. Statistical analyses were performed with STATA version 13.0 (Stata Corporation, College Station, TX, USA).
Results
The median age at the time of cancer diagnosis was 59.4 years, and 51% of the patients were male. Localized cancer was found in 38% of the patients; 30% had regional spread and 17% had distant metastasis at the time of cancer diagnosis. For 14%, cancer stage was coded as 'unknown' in the NCRs. The frequency of unknown cancer stage varied with cancer type, and was lowest for ovarian cancer (3%) and highest for prostate cancer (30%) ( were associated with a positive, significant IRD of VTE during the first year after cancer diagnosis as compared with localized disease. IRDs remained positive and significantly different from zero for both regional spread and distant metastasis as compared with localized disease 5 years after cancer diagnosis. However, the majority of VTEs contributing to the IRDs during the first 5 years after cancer diagnosis occurred within the first year, and this was most pronounced in patients with distant metastases (Table 2) . When each type of cancer was examined, the number of VTE events was rather low in some of the groups, so the IRD could merely indicate trends. During the first year after cancer diagnosis, the IRD for regional spread versus localized disease varied from negative values, to slightly over zero in breast cancer, to 37.6 9 10 À3 p-y (95% CI À 23.7 to 99.0) in uterine cancer (Table 2) . Distant metastasis as compared with localized disease was associated with IRDs ranging from a negative value for uterine cancer, to 187.0 9 10 À3 p-y (95% CI À 6.7 to 380.8) for pancreatic cancer. In the 5-year period after cancer diagnosis, the IRDs represented exclusively VTEs that occurred in the first year in upper gastrointestinal and distant metastatic pancreatic and bladder cancer. The CIP of VTE stratified by cancer stage is shown in Fig. 1 . The highest CIP of VTE was observed within the first year after cancer diagnosis, most distinctly in patients with distant metastasis. The CIPs of VTE in different cancer types stratified by cancer stages are shown in Fig. 2 . The CIP was generally highest in the groups with distant metastasis, but varied considerably in patients with regional spread, from almost the same as in localized disease, over an intermediate CIP, and to almost as high as in distant metastasis. The CIP of VTE in participants with prostate cancer, however, was low for all stages. In groups with unknown cancer stage, the CIP of VTE was typically in between the estimates for localized disease and distant metastasis (Table S2) .
Regional spread (HR 2.6, 95% CI 1.7-4.0) and distant metastasis (HR 6.8, 95% CI 4.5-10.4) as compared with localized disease were associated with a significantly increased risk of VTE in the first year after cancer diagnosis in the regression analysis of all cancer types combined (Table 3 ). This association was even stronger for distant metastatic colorectal, upper gastrointestinal and bladder cancer than for localized disease. The HR for colorectal cancer was 16.5, with a 95% CI of 3.6-74. 6 . In addition to distant metastasis, regional spread as compared with localized disease was associated with an increased HR of VTE during the first year after diagnosis of colorectal cancer (HR 7.3, 95% CI 1.7-30.1). There was also a trend towards a higher risk of VTE in patients with regional spread of lung, upper gastrointestinal, pancreatic and uterine cancer.
Discussion
In this large population-based cohort study, we estimated the IR and IRD of VTE according to initial cancer stage in 10 distinct types of solid cancer. Our study showed that the association between cancer stage and IR of VTE differed substantially between different cancer types. For lung, colorectal, upper gastrointestinal and ovarian cancer, we observed statistically significant positive IRDs of VTE in patients with distant metastasis as compared with localized disease during the first year after cancer diagnosis. For the remaining six cancer types, IRDs were positive except for uterine cancer. Also, regional spread of cancer was associated with positive IRDs of VTE as compared with localized disease for upper gastrointestinal, pancreatic, uterine, ovarian, lung and colorectal cancer.
The risk of VTE is often expressed as HRs, which contribute to our understanding of the strength of the relationship, in this case between cancer stage and the risk of VTE. However, the HR is less useful without a basic IR for a clinically meaningful interpretation. This is illustrated by the equal HRs of VTE for distant metastasis in lung and breast cancer as compared with localized disease (Table 3) . Owing to a high IR of VTE in localized lung cancer, the HR did not reflect the considerable IRD (83 9 10 À3 p-y)
in distant metastatic lung cancer as compared with localized lung cancer. The non-significant IRD of breast cancer (29 9 10 À3 p-y) was, however, associated with a high HR of VTE that was comparable to that in lung cancer.
Comparison of the presented risk estimates with estimates from previous studies on single cancer types is challenging, owing to different censoring points [15, 18] , different cancer stage definitions [9, 14, 17, 25] , and varying baseline characteristics [16, 24] . Most previous studies reporting cumulative IRs of VTE in cancer populations treated death as a censoring event, which tends to result in overestimation of the absolute risks, especially when the mortality rate is high [42, 43] . Mortality was taken into account in a newly published very large populationbased study on VTE incidence in cancer, thus providing good estimates of IRs in most cancer types [44] . The IRs of VTE in different cancer types were higher than in our study, mainly because we did not include asymptomatic 2116 (20) 2117 (20) 2134 (20) 2123 (20) 4003 (38) 3238 (30) 1822 (17) 1520 (14) Cancer site (ICD-10 codes) Lung (C330-C349) 1557 852 705 265 (17) 297 (19) 335 (22) 380 (24) 280 (18) 277 (18) 480 (31) 676 (43) 124 (8) Colorectal (C180-C189 399 (19) 370 (18) 417 (20) 538 (26) 627 (30) 1055 (51) 257 (12) 136 (7) Upper GI (C150-C159 92 (18) 84 (17) 100 (20) 145 (29) 104 (21) 218 (43) 108 (21) 77 (15) Pancreatic (C250-C259) 402 221 181 57 (14) 84 (21) 80 (20) 81 (20) 100 (25) 39 (10) 196 (49) 104 (26) 63 (16) Breast (C500-C509) 2194 0 2194 777 (35) 527 (24) 411 (19) 272 (12) 207 (9) 1094 (50) 799 (36) 77 (4) 224 ( 561 (24) 596 (25) 518 (22) 1083 (46) 266 (11) 304 (13) 694 (30) Bladder (C660-C689) 540 416 124 84 (16) 80 (15) 96 (18) 117 (22) 163 (30) 305 (57) 77 (14) 27 (5) 131 (24) Kidney (C640-C649) 300 184 116 56 (19) 54 (18) 54 (18) 60 (20) 76 (26) 141 (47) 41 (14) 72 (24) 46 (15) Uterine (C540-C549 82 (22) 72 (19) 60 (16) 54 (14) 279 (74) 66 (18) 16 (4) 16 (4) Ovarian (C560-C569) 284 0 284 85 (30) 52 (18) 54 (19) 51 (18) 42 (15) 54 (19) 40 (14) 181 (64) 9 (3) GI, gastrointestinal.
VTEs. Existing studies did, in general, find higher risks of VTE in patients with regionally spread cancer and distant metastasis than in those with localized disease, but the risk seems to vary by cancer type, from distinct associations between cancer stages and the risk of VTE for lung and colorectal cancer [14, 15, 17, 18] , to weaker associations for pancreatic, breast and prostate cancer [19, 20, 22, 25] . Our results showed that cancer type and the time since cancer diagnosis were important in the development of VTE (Fig. 2) . Through the first year, distant metastasis was generally associated with higher risks, whereas the association for regional spread was much more variable, ranging from no association when compared with localized disease to an association as strong as observed for distant metastasis (but mainly lower). During years 2-5, these associations were attenuated.
VTE in cancer is a multifactorial complication. Interindividual factors (patient characteristics), cancer- Table 2 Incidence rates of venous thromboembolism (VTE) and incidence rate (IR) differences (IRDs) of VTE as compared with localized disease during the first year after cancer diagnosis and until 5 years after cancer diagnosis CI, confidence interval; GI, gastrointestinal; p-y, person-years.
© 2017 International Society on Thrombosis and Haemostasis related treatments (chemotherapy, antiangiogenetic therapy, surgery, and intravenous catheters) and cancerspecific factors contribute to the individual risks of VTE in cancer patients [45, 46] . The diverse biology of malignant cancers probably gives rise to hypercoagulable states by different mechanisms, and the factors triggering a VTE depend, in some cancer types, also on the extent of disease, but actually mainly on the cancer type. The biological diversity of solid cancers is reflected in the very different IRs of VTE across cancer types and stages as presented in this study.
The major limitation of our study is the low number of events in some groups, preventing us from drawing firm conclusions. However, we provide valuable information in terms of stage-specific IRs of VTE, which only can be calculated when data on person-time at risk are available. As the data are derived from a large cohort, the risks of VTE in patients with different cancer types are comparable (although the CIs may be broad) within the cohort. In addition, we did not have information on anticancer treatment, which has important effects on the risk of VTE. We may have missed cases of VTE among the cancer patients if the VTE was not registered or diagnosed because of long and complex hospital admissions. This might be more common in patients with advanced cancer stages, and thereby bias our estimates towards null. Likewise, even though computed tomography scans were accessible for most, if not all, cancer patients during the entire study period, it is possible that technically improved diagnostic imaging for cancer staging over the study period and ongoing refinement of definitions of cancer stages may have changed the staging, but this will tend to draw the differences in VTE incidence between cancer stages towards null. The TNM staging system has been evaluated in breast cancer cases in the Danish NCR, and the reported overall completeness of 85% is similar to the completeness of cancer stage data in the Danish NCR from 1988 to 1992, so we consider the inclusion of cancer diagnoses coded in either staging system to be reasonable [30, 47] . Our data contribute to an emerging understanding that cancer stage may not be an independent risk factor for VTE in all cancer types as such, but that the risk actually depends more on the cancer type for some cancers. In summary, both regional spread and distant metastasis were associated with significantly higher IRDs of VTE than localized disease in patients with overt cancer. Generally, distant metastases were associated with a substantially higher risk of VTE, whereas regional spread was less strongly associated with VTE incidence. However, in some cancer types (e.g. prostate cancer), regional spread and distant metastasis were hardly associated with VTE development. 
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